Isles A F
Royal Children's Hospital, Herston, Brisbane.
Aust Fam Physician. 1993 Dec;22(12):2163-7.
Practitioners prescribing inhaled corticosteroids for children need to be aware of the potential for systemic side effects, particularly in relation to effects on growth, bone metabolism and adrenal function. There is a need for further long-term studies to assess the risk of side effects especially in younger children. Until further data are available, caution is required in transposing current safety data from adults and older children to the very young. Precise safety thresholds cannot be defined at present. The risk-benefit ratio of corticosteroids must be assessed for each patient and reassessed at intervals during continuing therapy. Strategies to decrease the dose and minimise the potential for systemic side effects should be a routine part of asthma management. Concern about potential side effects should not outweigh the need for effective symptomatic control. Children with asthma should not be exposed to the risks of either under treatment or overtreatment of their asthma.
为儿童开具吸入性糖皮质激素的从业者需要意识到其存在全身副作用的可能性，尤其是对生长、骨代谢和肾上腺功能的影响。需要进一步开展长期研究以评估副作用风险，特别是在年幼儿童中。在获得更多数据之前，将目前来自成人和大龄儿童的安全数据应用于婴幼儿时需谨慎。目前尚无法确定精确的安全阈值。必须为每位患者评估糖皮质激素的风险效益比，并在持续治疗期间定期重新评估。减少剂量并将全身副作用的可能性降至最低的策略应成为哮喘管理的常规组成部分。对潜在副作用的担忧不应超过有效对症治疗的需求。哮喘患儿不应面临哮喘治疗不足或过度治疗的风险。
